Workflow
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Rocket PharmaceuticalsRocket Pharmaceuticals(US:RCKT) GlobeNewswire News Roomยท2025-05-28 22:25

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rocket Pharmaceuticals and its officers or directors following a serious adverse event in a clinical trial that led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an unexpected serious adverse event (SAE) related to its investigational gene therapy RP-A501 for Danon disease, which involved clinical complications from capillary leak syndrome [3]. - Following the SAE, Rocket voluntarily paused further dosing in the Phase 2 pivotal trial, and the FDA placed a clinical hold on the trial for further evaluation [3]. - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3]. Group 2: Market Reaction - The announcement of the SAE resulted in Rocket's stock price falling by $3.94 per share, a decrease of 62.84%, closing at $2.33 per share on May 27, 2025 [3]. Group 3: Legal Context - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation regarding Rocket Pharmaceuticals [1][4].